Walden Biosciences
Founded 2020 · 22 employees on LinkedIn · 2 known investors
Walden Biosciences is a clinical-stage biotech company developing disease-modifying therapies that selectively target the kidney to treat the underlying drivers of kidney disease. Its pipeline aims to change the treatment landscape for patients with degenerative kidney diseases.
Also known as Walden BioSciences · Walden Biosciences, Inc.
Investors · 2
Company profile
researched Aug 2026Walden Biosciences is a Cambridge, Massachusetts biotechnology company developing highly targeted, disease-modifying therapies for kidney disease. The company's stated aim is to treat the underlying biology of renal disease and reverse disease progression rather than only slow it, positioning its medicines as an alternative to dialysis or transplantation for patients with degenerative and end-stage kidney disease.
The scientific approach combines antibodies and small molecules. One program targets soluble urokinase plasminogen activating receptor (suPAR), a circulating protein associated with acute kidney injury and chronic kidney disease, with the goal of reducing inflammation and improving kidney function. A second program is designed to preserve podocytes — the filtration cells of the kidney — by activating the enzyme dynamin, which maintains the structure of the glomerular filtration apparatus. Management has described using both reductionist analysis of individual components and a holistic, systems-based view of the kidney's mechanical and biochemical functions.
The company's lead disclosed clinical candidate is WAL0921, referenced in third-party pipeline analyses of focal segmental glomerulosclerosis alongside sparsentan (Travere Therapeutics) and DMX-200 (Dimerix Bioscience). In September 2025 Walden announced initiatives to advance its clinical pipeline and support a Phase 2 program for WAL0921 in rare kidney diseases.
Founding story
Walden Biosciences was founded in 2020 to commercialize research conducted by faculty at Rush University and Harvard University. Its co-founders include Jochen Reiser, chairman of the Department of Internal Medicine at Rush University Medical Center; Ralph C. Brown, professor of medicine at Rush Medical College; Sanja Sever, associate professor of medicine at Harvard Medical School; and Ari Nowacek, a principal at ARCH Venture Partners. Blaine McKee served as president and chief executive officer at launch, with Alex Duncan as chief scientific officer.
Business model
Walden Biosciences operates as a research and development-stage biopharmaceutical company, discovering and developing proprietary therapeutic candidates targeted at the kidney. The sources describe drug programs advancing toward and into clinical trials rather than commercialized products, and financing has come from venture capital and corporate venture investors rather than product revenue.
No revenue model is described in the sources; the company is pre-commercial and funded by equity investment.
Traction
Walden raised $51m in Series A funding at its October 2020 launch and had approximately 12 employees at that time. As of 2025 its lead candidate WAL0921 was the subject of a Phase 2 program in rare kidney diseases and appeared in third-party analyses of the focal segmental glomerulosclerosis pipeline.
Latest developments
In January 2025 Walden appointed Howard Mayer, M.D. to its Board of Directors. On September 4, 2025 the company announced key initiatives to advance its clinical pipeline and support a Phase 2 program for WAL0921 in rare kidney diseases. Third-party pipeline reports published in 2025 list WAL0921 among emerging focal segmental glomerulosclerosis therapies, and a June 2026 report lists the company among participants in IgA nephropathy development.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Walden is an early clinical-stage entrant in nephrology drug development. Third-party pipeline analyses place WAL0921 among a group of emerging focal segmental glomerulosclerosis candidates that includes sparsentan (Travere Therapeutics) and DMX-200 (Dimerix Bioscience), and identify the company among a larger field of firms active in IgA nephropathy development.
Walden describes its differentiation as kidney-specific targeting: delivering therapies that act at the site of drug action in the kidney, based on a mechanistic understanding of kidney-specific biological pathways in health and disease. Its dual antibody/small-molecule strategy against suPAR and dynamin-mediated podocyte preservation is framed as addressing underlying disease drivers rather than managing downstream factors such as hypertension or glucose levels.
Technology
Two therapeutic modalities are described. The first is directed at soluble urokinase plasminogen activating receptor (suPAR), a protein associated with kidney disease, aiming to reduce inflammation and improve kidney function. The second activates dynamin, an enzyme that maintains the structure of the kidney's filtration apparatus, to preserve podocytes. The company describes a systems-based approach combining reductionist study of individual components with a holistic view of the kidney's mechanical and biochemical functions.
Go-to-market
Sources do not describe a commercial go-to-market approach; activity to date centers on preclinical and clinical development of proprietary drug candidates, supported by venture and corporate venture financing.
Patients with kidney disease, including acute kidney injury, chronic kidney disease, end-stage renal disease and rare kidney diseases such as focal segmental glomerulosclerosis; Fierce Biotech cites roughly 37 million people in the U.S. living with kidney disease, more than 1 in 7 American adults.
Geography
Headquartered in Cambridge, Massachusetts, United States; listed as a member of the Massachusetts biotechnology industry association MassBio. No other locations are described in the sources.
History
The company was founded in 2020 by faculty from Rush University and Harvard University together with an ARCH Venture Partners principal, and emerged publicly on October 6, 2020 with a $51m Series A co-led by ARCH Venture Partners and UCB Ventures. At launch it employed about 12 people in Cambridge, Massachusetts, with plans to move two programs into the clinic. By 2025 the company was reporting board and pipeline milestones: Howard Mayer, M.D. joined the Board of Directors in January 2025, and in September 2025 Walden announced initiatives to advance its clinical pipeline and support a Phase 2 program for WAL0921 in rare kidney diseases. Steven Gillis is listed as Chairman of the Board and Jochen Reiser as scientific co-founder and scientific advisory board member.
Risks & controversies
The sources do not report controversies. General risks implied are those of clinical-stage drug development, including unproven efficacy of novel targets such as suPAR and dynamin activation, and competition from multiple companies developing therapies for focal segmental glomerulosclerosis and IgA nephropathy.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsPress release announcing initiatives to advance the clinical pipeline and support the Phase 2 program for WAL0921 in rare kidney diseases; also carried via GlobeNewswire dated September 12, 2025.
The Cambridge, MA company publicly launched with $51m in Series A financing co-led by ARCH Venture Partners and UCB Ventures, to advance antibody and small-molecule kidney programs into the clinic and expand the 12-person team.
$51M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 5
primary sources listed
- Walden Bioscienceswaldenbiosciences.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Walden Biosciences do?
- Cambridge, MA clinical-stage biotech developing kidney-targeted antibody and small-molecule therapies for kidney disease.
- Who are Walden Biosciences's investors?
- Walden Biosciences's investors include ARCH Venture Partners, Pandect Bioventures.